Xalatan®
Latanoprost 0.005% · ophthalmic solution
Antiglaucoma
Approved uses
Open-angle glaucoma or ocular hypertension
One drop in the affected eye(s) once daily in the evening; not to exceed once daily.
IOP falls 3 to 4 hours after dosing, peaks at 8 to 12 hours, and lasts 24 hours with a 6.7 mmHg drop.
OFF-LABELNot in the FDA label for this product
Chronic angle-closure glaucoma
0.005% solution, one drop once daily at 9 PM (trial regimen), 12 weeks.
RCT · n=275
Randomized, double-masked, multicenter 12-week trial in chronic angle-closure glaucoma (latanoprost n=137, timolol n=138): mean change in daily IOP was -8.2 mmHg versus -5.2 mmHg with timolol BID, difference -3.0 mmHg (95% CI -4.0 to -2.1, P<0.001), favoring latanoprost, and more patients reached each prespecified target IOP. The formulation studied was the preserved 0.005% solution.
Pediatric glaucoma
0.005% solution, one drop once daily at 8 PM (trial regimen, ages 0 to 18 years), 12 weeks.
RCT · n=137 · not superior
Phase 3, randomized, double-masked, 12-week multicenter trial, 137 treated (primary congenital and non-congenital glaucoma): mean IOP reduction at week 12 was 7.2 mmHg versus 5.7 mmHg with timolol, difference 1.5 mmHg (95% CI -0.8 to 3.7, P=0.21), meeting the noninferiority margin without demonstrating superiority; responder rates 60% versus 52% (P=0.33) and both agents well tolerated over 3 months. This label states pediatric safety and effectiveness are not established.
Contraindications
Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredient in this product.
0.005% (50 mcg/mL) ophthalmic solution, 2.5 mL fill in a 5 mL bottle, package of 1 bottle
Prostaglandin F2alpha analogue supplied as an isopropyl ester prodrug that corneal esterases hydrolyze to the active acid; it is believed to reduce IOP by increasing the outflow of aqueous humor, and studies in animals and man suggest the main mechanism is increased uveoscleral outflow, which class reviews attribute to matrix metalloproteinase remodeling that widens the spaces between ciliary muscle fibers. IOP reduction starts about 3 to 4 hours after instillation, maximum effect is reached after 8 to 12 hours, and IOP reduction is present for at least 24 hours.
Warnings & Precautions
- Pigmentation: Latanoprost has been reported to cause changes to pigmented tissues, most often increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as latanoprost is given and reflects more melanin in melanocytes, not more melanocytes. Iris pigmentation is likely to be permanent after discontinuation, effects beyond 5 years are not known, and patients should be informed of the possibility of increased pigmentation.
- Iris pigmentation: Typically, the brown pigmentation around the pupil spreads concentrically toward the periphery of the iris, and the change may not be noticeable for several months to years. Neither nevi nor freckles of the iris appear to be affected. Treatment can be continued in patients who develop noticeably increased iris pigmentation, but these patients should be examined regularly.
- Periorbital and lash changes: Eyelid skin darkening, and gradual changes to eyelashes and vellus hair in the treated eye (increased length, thickness, pigmentation, number, and misdirected growth) may occur; periorbital tissue pigmentation reported reversible in some patients, eyelash changes usually reversible upon discontinuation.
- Intraocular inflammation: Caution with a history of iritis or uveitis, and generally not for use with active intraocular inflammation, which may be exacerbated.
- Macular edema: Macular edema including cystoid macular edema has been reported; caution in aphakia, in pseudophakia with a torn posterior lens capsule, and with other known risk factors.
- Herpetic keratitis: Reactivation of herpes simplex keratitis has been reported; caution with a history of it, and avoid in active herpes simplex keratitis, which may be exacerbated.
- Bacterial keratitis: Reported with inadvertently contaminated multiple-dose containers, in most cases in patients with concurrent corneal disease or a disrupted ocular epithelial surface.
- Contact lens use: Preserved with 0.02% benzalkonium chloride, which may be absorbed by contact lenses; remove lenses before instillation and reinsert 15 minutes after.
- Paradoxical elevations in IOP: The dosage should not exceed once daily, and combined use of two or more prostaglandins or prostaglandin analogs is not recommended; giving these products more than once daily may decrease the IOP lowering effect or cause paradoxical elevations in IOP.
- Precipitation: Precipitation occurs in vitro when thimerosal drops are mixed with this solution; separate concurrent topical drops by at least 5 minutes.
Common Side Effects
- Ocular, 5% to 15%: foreign body sensation 13%, punctate keratitis 10%, stinging 9%, conjunctival hyperemia 8%, blurred vision 8%, itching 8%, burning 7%, increased iris pigmentation 7% (n=460 vs timolol n=369 in three controlled trials).
- Ocular, 1% to 5%: excessive tearing 4%, eyelid discomfort or pain 4%, dry eye 3%, eye pain 3%, eyelid margin crusting 3%, eyelid erythema 3%, photophobia 2%, eyelid edema 1%, blepharitis 1%.
- Discontinuation: fewer than 1% stopped therapy for intolerance to conjunctival hyperemia.
- Ocular, postmarketing: intraocular inflammation (iritis/uveitis), macular edema including cystoid macular edema, herpes keratitis, keratitis, corneal edema and erosions, deepening of the eyelid sulcus, trichiasis, iris cyst, eyelid skin darkening, conjunctivitis, pseudopemphigoid of the conjunctiva.
- Systemic, 1% to 3%: upper respiratory infection, nasopharyngitis or influenza 3%, myalgia, arthralgia or back pain 1%, rash or allergic skin reaction 1%.
- Systemic, postmarketing: asthma and exacerbation of asthma, dyspnea, headache, dizziness, angina including unstable angina, palpitations, chest pain, nausea, vomiting, pruritus, toxic epidermal necrolysis.
Pregnancy: No adequate and well-controlled studies in pregnant women. IV latanoprost given to pregnant rabbits and rats through organogenesis produced malformations, embryofetal lethality, and spontaneous abortion at clinically relevant doses, with post-implantation loss in rabbits at 1.3 times the maximum recommended human ophthalmic dose and cleft palate in rats at 3.2 times.
Lactation: Excretion in human milk is unknown; exercise caution in a nursing woman, and weigh the benefits of breastfeeding against maternal need and potential effects on the breastfed child.
Safety and effectiveness not established in pediatric patients.